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Introduction
The ErbB/HER family of receptor tyrosine kinases (RTK) plays critical roles in development and cancer (1) . These receptors include epidermal growth factor receptor (EGFR)/ErbB1, HER2/ErbB2, HER3/ ErbB3 and HER4/ErbB4. Numerous ligands have been identified which interact with all HER family receptors, with the exception of HER2. Ligand binding activates multiple downstream signal transduction pathways. HER2 is the common co-receptorfor the other HER family members. Association of HER2 with HER3 is the most potent signaling complex formed in this receptor family (2, 3) . HER3 is considered a pseudo-kinase, (4, 5) but can potently activate phosphatidylinositol 3-kinase (PI3-K) signaling upon dimerization with other HER family members (6) .
In addition to growth factor regulation of cell proliferation and differentiation, recent reports show an important role for multiple RTK ligands in resistance to kinase inhibitors (7) (8) (9) . The HER3 ligand, neuregulin 1 (NRG-1), was recently shown to mediate resistance to chemotherapeutic agents as well (10) .
Moreover, HER3 was reported to mediate resistance to EGFR, HER2 and PI3-K inhibitors. Treatment resulted in HER3 activation, leading to attenuation of the response to kinase inhibition (11, 12) .
Trastuzumab (Herceptin®), a humanized HER2 antibody that binds domain IV of the HER2 extracellular domain (ECD), is used in combination with chemotherapy for treatment of HER2-positive breast cancer. Proposed mechanisms of trastuzumab action include inhibition of ECD shedding, disruption of downstream signal transduction pathways, induction of cell cycle arrest, inhibition of DNA repair, decreased angiogenesis, and mediation of antibodydependent cellular cytotoxicity (ADCC) (13) . Clinical benefit from trastuzumabcontaining therapy, however, can be limited, especially in the metastatic setting, necessitating development of alternate forms of treatment (14, 15) . We developed a cytotoxic drug-conjugate of trastuzumab by covalently linking the anti-mitotic agent DM1 to trastuzumab through a stable MCC linker.
Trastuzumab emtansine (T-DM1) potently inhibits growth of trastuzumabsensitive and -insensitive HER2-amplified cancer cells and shows a favorable safety profile in preclinical toxicity studies (16) . T-DM1 activity has been evaluated in Phase II and III clinical trials in patients with HER2-positive locally advanced or metastatic breast cancer (mBC, ref. 17, 18) . T-DM1 (Kadcyla®) was recently approved for treatment of patients with HER2-positive metastatic breast cancer who have received prior treatment with Herceptin® and a taxane chemotherapy, based on data showing significantly prolonged progression-free and overall survival and less toxicity compared to standard-of-care treatment, lapatinib (Tykerb®) plus capecitabine (Xeloda®) (19) .
In addition to trastuzumab, pertuzumab is a HER2-specific humanized antibody with efficacy demonstrated in mouse xenograft models of breast, lung, prostate and ovarian cancer (20) (21) (22) (23) . Pertuzumab binds domain II of the HER2 ECD, preventing ligand-dependent association of HER2 with other HER family members (24) and demonstrated clinical activity as a single agent and in combination with chemotherapy in ovarian, non-small cell lung and prostate cancer (25) (26) (27) (28) (29) . Pertuzumab combined with trastuzumab has anti-tumor activity in cell culture (30) and animal models of HER2-amplified cancer (23, 31) , and in patients with HER2-positive metastatic breast cancer (32, 33) . Combining pertuzumab, trastuzumab, and docetaxel significantly improves the pathological complete response rate in the neoadjuvant setting compared to treatment without pertuzumab (33) . In June 2012, the US FDA approved Pertuzumab (Perjeta®) in combination with Herceptin® and chemotherapy for treatment of patients with HER2-positive mBC who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease (34) . We therefore explored the potential of combining T-DM1 with pertuzumab in models of HER2-amplified breast and lung cancer. Our data underscore the feasibility of using multiple strategies to target HER2-positive cancer. Human breast tumor lines BT-474, SK-BR-3, UACC-812, ZR-75-30,   HCC1954 and MDA-MB-175-VII; and the non-small cell lung carcinoma line Calu-3 were obtained from the American Type Culture Collection. KPL-4 breast cancer cells were provided by J. Kurebayashi (35) . Cells were maintained as previously described (16) . Trastuzumab emtansine (T-DM1), pertuzumab, N297A-pertuzumab (38) , and E. coli-derived NRG-1β (EGF domain) were produced at Genentech, Inc. Unconjugated DM1 was obtained from ImmunoGen, Inc. and chemotherapeutic drugs from Sigma Aldrich. Western blot antibodies were from R&D Systems (cleaved PARP), Cell Signaling Technology (phospho-HER3, phospho-Akt, Akt), and Santa Cruz Biotechnology, Inc. (HER3).
Materials and Methods

Cell lines and reagents
Cell viability and apoptosis assays
Cell viability and apoptosis assays were performed as described (16) . T-DM1, pertuzumab or the combination was added to cells; treatments were in duplicate in order to fit all groups onto one plate and experiments were repeated 5 times. Studies performed without NRG-1β were in medium supplemented with 10% FBS; studies with NRG-1β (2 nM) were in 1% FBS-containing medium. Cell viability was measured at 3 (SK-BR-3, KPL-4) or 5 (BT-474, Calu-3) days after drug addition. Assays to test NRG-1β effects on T-DM1 or chemotherapeutic agent activity were 3 or 5 days (n=3 per group) and studies were performed 3 times. Combination Index (C.I.) values, as described by Chou and Talalay (36), were generated using CalcuSyn software (Biosoft, Inc). ADCC assays were performed as described (37) using CytoTox-ONE
™
Homogeneous Membrane
Integrity Assay (Promega Corp.). Treatments were T-DM1 alone or combined with pertuzumab or the Fc mutant N297A-pertuzumab; trastuzumab and anti-gD isotype-matched antibody were positive and negative controls, respectively.
Western analysis
For measuring PARP (poly (ADP-ribose) polymerase) cleavage, MDA-MB-175-VII cells were seeded and allowed to adhere for 48 h. T-DM1 (10 μg/mL), pertuzumab (100 μg/mL) or the combination was added and cells incubated for 7 48 or 72 hours. For experiments with NRG-1β, SK-BR-3, Calu-3, KPL-4, and MDA-MB-175-VII were plated and allowed to adhere overnight. Cells were then starved in medium with 0.1% FBS for 24 h. NRG-1β (1 nM) was added to all cells, except MDA-MB-175-VII, after a 1 hour pre-treatment with pertuzumab or N297A-pertuzumab, T-DM1 or the combination. After 15 minutes or 24 hours, cells were lysed in RIPA buffer and Western blotting procedures performed as described previously (16) .
In vivo efficacy studies
MDA-MB-175-VII breast cancer xenograft studies were performed as described previously (21) . KPL-4 breast tumor cells were inoculated (3 x 10 (Fig. 1D) . From these studies, we conclude that anti-tumor activity of combination treatment in vivo is likely due to enhanced anti-signaling activities, not increased ADCC.
T-DM1 combined with pertuzumab in HER2-amplified lung and breast cancer cells.
Additional studies were performed in tumor cells with 3+ HER2 expression. NRG-1β was included in these experiments as these cells do not express endogenous ligand. In Calu-3, BT-474 and SK-BR-3 cells, T-DM1 was more active than pertuzumab, while the combination was more potent than single agent treatment ( Fig. 2A, B Calu-3 and BT-474 cell growth was stimulated by NRG-1β, while SK-BR-3 growth was unaffected under these experimental conditions. Thus, the enhancement by pertuzumab of T-DM1 activity in the presence of NRG-1β was independent of NRG-1β mitogenic activity. In contrast, no combination effect was observed in cells treated in the absence of NRG-1β; i.e. pertuzumab did not enhance the growth inhibitory effect of T-DM1 under ligand-independent conditions ( Fig. 2A , B, C right panels). In KPL-4 breast cancer cells, T-DM1 cytotoxicity was not increased by pertuzumab in ligand-dependent (Fig. 2D, left panel) or ligand-independent (Fig. 2D, right panel) conditions.
Inhibition of T-DM1 cytotoxicity by NRG-1β
In the above experiments, it was noted that the cytotoxic response to T-DM1 was reduced in the presence of NRG-1β. We therefore investigated NRG- (Fig. 3A, right panels) . In contrast, NRG-1β did not block T-DM1 activity in KPL-4 and HCC1954 breast cancer cells (Fig. 3B) . Interestingly, these two breast cancer lines harbor activating PIK3CA mutations (H1047R for both, (40) , whereas the 4 cell lines which displayed reduced T-DM1 activity in the presence of NRG-1β do not (40) . Finally, the addition of NRG-1β also inhibited T-DM1- 
caspase activity. Blockade of NRG-1β signaling by the addition of pertuzumab fully restored the apoptotic response to T-DM1 (Fig. 3C and Supp. Fig. 3 left   panels) . Similar to the observations in proliferation assays, T-DM1-induced apoptosis in KPL-4 and HCC1954 cells was not reduced by NRG-1β (Fig. 3C and Supp. Fig. 3 right panels) . These results provide additional evidence for the rationale of blocking ligand-induced receptor activation with pertuzumab for optimal T-DM1 response in a subset of HER2-amplified cancer cells.
NRG-1β inhibits activity of anti-mitotic agents
The DM1 component of T-DM1 is a potent anti-mitotic agent (41) .
Additional studies were performed to determine if the protective effect of NRG-1β applied to free DM1 and to anti-mitotic agents used for breast cancer treatment.
Similar to the findings with T-DM1, NRG-1β reduced the cytotoxic effects of unconjugated DM1 as well as docetaxel and vinorelbine in BT-474 cells (Supp. In contrast, NRG-1β did not reduce the cytotoxic effects of these agents in KPL-4 cells (Supp. Fig. 4, right panels) . Overall, these data show NRG-1β inhibition of the cytotoxic activity of T-DM1, docetaxel and vinorelbine, further validating the importance of blocking NRG-1β activity with pertuzumab. 
Effects of T-DM1
p-HER3 and p-AKT, addition of pertuzumab to T-DM1 was required to inhibit AKT activation in the presence of NRG-1β.
In KPL-4 cells, NRG-1β transiently activated HER3, but not AKT, (Fig. 4 lower panels), likely due to mutational activation of the PI3K pathway.
Interestingly, T-DM1 treatment for 24 h suppressed both HER3 and AKT phosphorylation, with inhibition of p-AKT sustained even in the presence of NRG-1β. All treatment groups containing T-DM1 (T-DM1 alone, T-DM1 + NRG-1β, T-DM1 + pertuzumab, T-DM1 + pertuzumab + NRG-1β) showed similar inhibition of AKT phosphorylation, indicating that T-DM1 is sufficient to suppress AKT activation (Fig. 4, right panels 
T-DM1-pertuzumab combination studies in vivo
To further support our observation that T-DM1 combined with pertuzumab leads to enhanced anti-tumor effects, we performed in vivo combination studies in two HER2-amplified tumor xenograft models. In the Calu-3 lung cancer model, 25 mg/kg pertuzumab was administered once weekly for 3 weeks; T-DM1 was administered (1, 3, or 7 mg/kg) as a single intravenous injection at the start of the study. Pertuzumab treatment resulted in tumor growth delay (Fig. 5A efficacy was observed with 7 mg/kg T-DM1 compared with pertuzumab plus 3 mg/kg T-DM1. Pertuzumab with 7 mg/kg T-DM1 was the most active combination tested. Tumors regressed during and after treatment, with no regrowth until several weeks after treatment was stopped. Although more sustained tumor growth inhibition was reported in Calu-3 xenografts treated with pertuzumab and trastuzumab (23) , this was likely due to weekly antibody administration for the study duration (>45 days). In our studies, limited dosing allows for monitoring of tumor re-growth and calculation of time-to-tumor volume doubling (TTP). Log-rank tests for differences in TTP showed statistically significant differences between single agent treatment for pertuzumab or T-DM1 vs. the corresponding combination group (log-rank p-value for pertuzumab vs.
pertuzumab + 3 mg/kg T-DM1 = 0.008; log-rank p-value < 0.0001 for pertuzumab vs. pertuzumab + 7 mg/kg T-DM1, and for 1 or 3 mg/kg T-DM1 + pertuzumab vs.
T-DM1 alone; log-rank p-value = 0.0004 for 7 mg/kg T-DM1 vs. pertuzumab + 7 mg/kg T-DM1; see Supp. (Fig. 5A and B, left panels) . However, T-DM1 combined with pertuzumab or N297A-pertuzumab did not result in greater ADCC activity compared to T-DM1 or wild-type pertuzumab alone. As expected, N297A-pertuzumab and isotype-matched control antibody showed no activity.
These findings indicate that combination activity in vivo is likely due more to the anti-signaling activities of both T-DM1 and pertuzumab and warrant further investigation, in models such as KPL-4, of the role of stromal ligands in the response to pertuzumab in vivo.
Phase Ib study of T-DM1 combined with pertuzumab
A global, single-arm, Phase Ib/II study (TDM4373g) was conducted to investigate the safety and efficacy of T-DM1 plus pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer who had received prior systemic therapy for recurrent locally advanced or metastatic disease and in patients with newly diagnosed or previously untreated mBC (first-line). The primary objectives of this study included characterization of the safety and tolerability of this drug combination and to assess objective response rate (ORR) based on investigator assessment. In the 3+3 study design, (Supp. In the Phase Ib portion of the study, 3 patients received 3.0 mg/kg T-DM1 with the rest receiving the standard 3.6 mg/kg dose, for a total of 9 patients.
Patient demographics and baseline characteristics are shown in Supplemental Table 1 . The majority (8/9) of patients were white and had ECOG performance status of 1 (6/9). Patients had tumors that were either 3+ for HER2 expression by immunohistochemistry (IHC, 6/9) or positive by FISH (8/9). The median number of previous systemic therapies was eight. All patients had received prior trastuzumab and lapatinib therapy, as well as a taxane and capecitabine (see Supp. Table 2 ). Most patients (7/9) had also received prior anthracycline therapy.
During dose escalation, no patient treated with 3.0 mg/kg T-DM1 combined with pertuzumab developed a DLT. However, among the first 3 patients treated with 3.6 mg/kg T-DM1, one patient developed a DLT (Grade 4 thrombocytopenia), and the cohort was expanded to include 3 more patients, none of whom developed a DLT. Therefore, 3.6 mg/kg T-DM1 in combination with standard dose pertuzumab, administered every 3 weeks, was declared the recommended Phase II schedule. Table 1A shows adverse events (AEs) ≥ Grade 3 for the 9 patients. The most common ≥ Grade 3 AE was fatigue (3/9), with thrombocytopenia and lung complications each occurring in 1 out of 9 patients. All 9 patients experienced at least one adverse event of any grade; these are summarized in Supplemental Table 3 and included gastrointestinal, respiratory, musculoskeletal and skin disorders, as well as more general disorders such as fatigue, fever and chills.
Regarding objective response in Cohort 1 (n=3 patients who received 3.0 mg/kg T-DM1), 2 patients showed a partial response and 1 patient had stable disease. In Cohort 2 (n=6 patients receiving 3.6 mg/kg T-DM1), 2 patients had a partial response, 3 patients had stable disease, and 1 patient had disease progression as best response. Therefore, for the full Phase Ib cohort, the objective response rate was 44.4% (4/9, Table 1B ). Disease stability was maintained for at least 6 months for 2 of the 3 patients who had stable disease as best response. 
Discussion
With the approval by the US FDA in 1998, trastuzumab became widely integrated into standard treatment regimens for HER2-positive metastatic breast cancer (14) . Less than a decade later, favorable results were obtained with trastuzumab plus chemotherapy in early breast cancer (43) . More recently, trastuzumab in combination with cisplatin and a fluoropyrimidine for treatment of HER2-postive gastric/gastro-esophageal cancer was shown to extend survival in these patients (44) . Despite advances in the treatment of HER2-positive cancers, a subset of patients will show disease progression through treatment. (7) (8) (9) 46) . NRG-1β was also reported to rescue cells from the inhibitory effects of HER2 and EGFR kinase inhibitors (9, 47) . Moreover, the NRG-1β receptor, HER3, mediates inhibitor resistance; up-regulation and activation of HER3 was demonstrated in diverse tumor cell types in vitro in response to EGFR, HER2 and PI3-K kinase inhibitors (11, 12, 48, 49) . Our data showing NRG-1β-mediated resistance to the microtubule-targeted cytotoxic agents T-DM1, docetaxel and vinorelbine thus expand these observations beyond kinase inhibitors to cytotoxic agents.
Clinical activity of T-DM1 is being assessed in numerous Phase II and III trials. Phase II single arm trials of T-DM1 in patients with HER2-positive mBC who had received prior trastuzumab and/or lapatinib in addition to chemotherapy showed that, in these heavily pre-treated patients, the ORR ranged from 25-35% (17, 18) . Given the small sample size and the specifics of the patient population in the study reported here, it is difficult to compare the response rates for T-DM1 with pertuzumab to response rates for T-DM1 alone. An ongoing Phase III, 
